[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591157":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":57,"collaborators":26,"id":61,"slug":26,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rush protocol","EXPERIMENTAL","Milk and egg allergic children undergoing OIT following a Rush regimen",[13],"Biological: \"Rush\" regimen",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional protocol","ACTIVE_COMPARATOR","Milk and egg allergic children undergoing OIT following a Conventional regimen",[19],"Biological: \"Conventional\" regimen",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","\"Rush\" regimen","The \"rush\" regimen consists of the administration of several incremental doses daily, every day, over the first week of the Induction Phase (Part 1)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"\"Conventional\" regimen","The \"conventional\" regimen consists of the administration of only one incremental dose every 2 weeks, throughout all the Induction Phase (Part 1)",[15],[32],{"name":33,"affiliation":34,"role":35},"Dr. Pablo Rodriguez del Río, MD, PhD","Hospital Infantil Niño Jesús, Instituto de Investigación La Princesa","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Dr. Pablo Rodríguez del Río","CONTACT","+34915035900","prrio@yahoo.es",[43],{"facility":44,"status":45,"city":46,"state":26,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hospital Infantil Universitario Niño Jesús. Avenida de Menéndez Pelayo, número 65","RECRUITING","Madrid","28009","Spain",{"type":50,"coordinates":51},"Point",[52,53],-3.70256,40.4165,{"lat":53,"lon":52},[56],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Pablo Rodríguez del Rio","Sponsor-Investigator","100591157",false,"NCT06976775","Comparison Between a Rush and a Conventional Oral Immunotherapy Protocol to Treat Cow's Milk and Hen´s Egg Allergy. CompITO Study","Comparative Analysis Between Two Oral Immunotherapy Schemes in Cow´s Milk and\u002For Hen´s Egg Allergic Children to Improve Treatment Efficiency and Identify Response Biomarkers. CompITO Study","compITO","Inclusion Criteria:\n\n* Patients 6 to 16 years old\n* sIgE levels to milk 0.35 to 35kUA\u002FL for milk allergic subjects and egg 0.35 to 35kUA\u002FL for egg allergic subjects\n* Entry DBPCFC discrete milk eliciting dose (ED)≥ 22.2mg of milk protein and discrete egg ED≥18.5mg of egg protein, that are the population-based reference values for the ED20\n* Having a mild to moderate food allergy severity per DEFASE score (\\\u003C13 points)\n\nExclusion Criteria:\n\n* sIgE levels to milk \\>35kUA\u002FL for milk allergic subjects and egg \\> 35kUA\u002FL for milk allergic subjects\n* Entry DBPCFC discrete milk ED\\\u003C22.2mg of milk protein or discrete egg ED\\\u003C18.5mg of egg protein\n* Entry DBPCFC discrete ED for milk\\>2112mg of milk protein (cumulative amount of 4193,7mg of milk protein) and egg discrete ED\\>1560mg of egg protein (cumulative amount of 3110.8mg of egg protein)\n* Having severe food allergy per DEFASE score (≥13 points)\n* Other exclusion criteria: uncontrolled asthma, FEV1\\\u003C70%, severe atopic dermatitis, Eosinophilic Esophagitis, non-IgE mediated allergy, having started SCIT 3 months before, or SLIT one week before. Pregnancy","ALL","6 Years","16 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76,77],"PHASE2","PHASE3","This study investigates the efficacy and safety of two different OIT schemes to treat milk and egg allergic children",[80,81,82],"Food Allergy in Children","Milk Allergy","Egg Allergy",[84,85,86,87,88,89,90,91,92,93,94,95,96,97],"Food immunotherapy","Allergy","Milk","Egg","Oral immunotherapy","Anaphylaxis","Mast cell activation test","Saliva","Blood","IgE","Food allergy","Sensitization","Children","Pediatric","2026-02-16",{"date":100,"type":101},"2026-02-18","ACTUAL",{"date":103,"type":101},"2025-06-03",{"date":105,"type":73},"2027-04-30",{"name":59,"class":6},1]